OBJECTIVE: To compare the Model for End-Stage Liver Disease (MELD) with the modified model including sodium (MELDNa) for predicting 180-day mortality in patients with alcoholic hepatitis (AH) and determine the subset in whom serum sodium may enhance 180-day mortality prediction. PATIENTS AND METHODS: We examined 26 patients with AH enrolled in a prospective trial between June 1, 2004, and June 30, 2007, at Mayo Clinic. Logistic regression analysis was done to assess the effect of MELD and MELDNa scores on 180-day mortality. The C statistic was derived to compare MELD with MELDNa in patients with and without ascites. RESULTS: MELD (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.05-1.47; P = .007; C statistic, 0.81) and MELDNa (OR, 1.24; 95% CI, 1.05-1.56; P = .008; C statistic, 0.78) were significant predictors of 180-day mortality in patients with AH. A MELD score of 27.0 and a MELDNa score of 28.0 had sensitivity of 76.5% and 87.5% and specificity of 64.9% and 52.5%, respectively. In patients with AH and ascites, MELDNa (OR, 2.27; 95% CI, 1.22-36.68; P = .008; C statistic, 0.97) was a better predictor of 180-day mortality than MELD (OR, 1.37; 95% CI, 1.07-2.12; P = .006; C statistic, 0.90). A MELD score of 29.0 and a MELDNa score of 34.0 had sensitivity of 85.7% and 83.3% and specificity of 31.0% and 16.7%, respectively. CONCLUSION: MELD and MELDNa were similar predictors of 180-day mortality; however, MELDNa was a better predictor of mortality than MELD in patients with ascites. Hyponatremia in patients with AH without ascites is not a predictor of mortality because it may have a dilutional basis secondary to excessive intake of low-osmolar alcohol.
OBJECTIVE: To compare the Model for End-Stage Liver Disease (MELD) with the modified model including sodium (MELDNa) for predicting 180-day mortality in patients with alcoholic hepatitis (AH) and determine the subset in whom serum sodium may enhance 180-day mortality prediction. PATIENTS AND METHODS: We examined 26 patients with AH enrolled in a prospective trial between June 1, 2004, and June 30, 2007, at Mayo Clinic. Logistic regression analysis was done to assess the effect of MELD and MELDNa scores on 180-day mortality. The C statistic was derived to compare MELD with MELDNa in patients with and without ascites. RESULTS: MELD (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.05-1.47; P = .007; C statistic, 0.81) and MELDNa (OR, 1.24; 95% CI, 1.05-1.56; P = .008; C statistic, 0.78) were significant predictors of 180-day mortality in patients with AH. A MELD score of 27.0 and a MELDNa score of 28.0 had sensitivity of 76.5% and 87.5% and specificity of 64.9% and 52.5%, respectively. In patients with AH and ascites, MELDNa (OR, 2.27; 95% CI, 1.22-36.68; P = .008; C statistic, 0.97) was a better predictor of 180-day mortality than MELD (OR, 1.37; 95% CI, 1.07-2.12; P = .006; C statistic, 0.90). A MELD score of 29.0 and a MELDNa score of 34.0 had sensitivity of 85.7% and 83.3% and specificity of 31.0% and 16.7%, respectively. CONCLUSION: MELD and MELDNa were similar predictors of 180-day mortality; however, MELDNa was a better predictor of mortality than MELD in patients with ascites. Hyponatremia in patients with AH without ascites is not a predictor of mortality because it may have a dilutional basis secondary to excessive intake of low-osmolar alcohol.
Authors: Jennifer Guy; Ma Somsouk; Stephen Shiboski; Robert Kerlan; John M Inadomi; Scott W Biggins Journal: Clin Gastroenterol Hepatol Date: 2009-06-26 Impact factor: 11.382
Authors: Helga Paula; Sumeet K Asrani; Nicholas C Boetticher; Rachel Pedersen; Vijay H Shah; W Ray Kim Journal: Am J Gastroenterol Date: 2010-02-23 Impact factor: 10.864
Authors: Nicholas C Boetticher; Craig J Peine; Paul Kwo; Gary A Abrams; Tushar Patel; Bashar Aqel; Lisa Boardman; Gregory J Gores; William S Harmsen; Craig J McClain; Patrick S Kamath; Vijay H Shah Journal: Gastroenterology Date: 2008-09-13 Impact factor: 22.682
Authors: Om K Pathak; Raju Paudel; Om B Panta; Hom P Pant; Bishnu R Giri; Baikuntha Adhikari Journal: Saudi J Gastroenterol Date: 2009 Jul-Sep Impact factor: 2.485
Authors: D Morales-Arráez; M Ventura-Cots; J Altamirano; J G Abraldes; M Cruz-Lemini; M R Thursz; S R Atkinson; S K Sarin; W Kim; R Chavez-Araujo; M F Higuera-de la Tijera; A K Singal; V H Shah; P S Kamath; A Duarte-Rojo; E A Charles; V Vargas; M Jager; P E Rautou; D Rincon; F Zamarripa; J C Restrepo-Gutiérrez; A Torre; M R Lucey; J P Arab; P Mathurin; A Louvet; G García-Tsao; J A González; E C Verna; R S Brown; J Argemi; C Fernández-Carrillo; A Clemente; E Alvarado-Tapias; E Forrest; M Allison; R Bataller Journal: Am J Gastroenterol Date: 2022-02-01 Impact factor: 12.045
Authors: Mercedes Amieva-Balmori; Scherezada María Isabel Mejia-Loza; Roberto Ramos-González; Felipe Zamarripa-Dorsey; Eli García-Ruiz; Nuria Pérez Y López; Eumir I Juárez-Valdés; Adriana López-Luria; José María Remes-Troche Journal: World J Hepatol Date: 2015-08-18
Authors: Tuyet A Nguyen; Jonathan P DeShazo; Leroy R Thacker; Puneet Puri; Arun J Sanyal Journal: Alcohol Clin Exp Res Date: 2016-05-05 Impact factor: 3.455
Authors: Beata Kasztelan-Szczerbinska; Maria Slomka; Krzysztof Celinski; Mariusz Szczerbinski Journal: Biomed Res Int Date: 2013-09-17 Impact factor: 3.411
Authors: Paul Manka; Lars P Bechmann; Frank Tacke; Jan-Peter Sowa; Martin Schlattjan; Julia Kälsch; Christoph Jochum; Andreas Paul; Fuat H Saner; Christian Trautwein; Guido Gerken; Ali Canbay Journal: BMC Gastroenterol Date: 2013-04-03 Impact factor: 3.067